The old adage " dont start something you cant finish" springs to mind. The lack of funding obviously precludes much advancement currently. https://www.profil.com/knowledge-center/trial-stages
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025